Disease · MONDO_0008233

pheochromocytoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pheochromocytoma. Diseases, record MONDO_0008233. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008233

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pheochromocytoma; Open Targets
Open Targets ID: MONDO_0008233; Open Targets
Other names: phaeochromocytoma; Open Targets
Disease Ontology: DOID:0050771; Disease Ontology
MeSH: D010673; MeSH
Highest stage of its drugs: Approval, for 4 of its 38 drugs, from ClinicalTrials.gov, PMDA and TTD; Open Targets

Drugs38

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IOBENGUANE I 131	CHEMBL1615779	Small molecule	Approval	ClinicalTrials.gov	8	7	0	Drugs and targets
IOBENGUANE I 123	CHEMBL1615777	Small molecule	Approval	ClinicalTrials.gov	5	5	0	Drugs and targets
METYROSINE	CHEMBL1200862	Small molecule	Approval	PMDA and TTD	2	0	0	Drugs and targets
IOBENGUANE SULFATE I 131	CHEMBL3989511	Small molecule	Approval	TTD	1	0	0	Drugs and targets
LUTETIUM OXODOTREOTIDE LU-177	CHEMBL4297545	Protein	Phase 2	ClinicalTrials.gov	4	4	1	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CATEQUENTINIB	CHEMBL4303201	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BELZUTIFAN	CHEMBL4585668	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 38

See all 38 drugs

Targets71

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	4	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Unknown	https://conductscience.org/library/genes/1441	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	3	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5156	Drugs and targets
CD274	Programmed cell death 1 ligand 1	2	Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	2	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
FGFR3	Fibroblast growth factor receptor 3	2	Fibroblast growth factor receptor 3 inhibitor	Phase 2	https://conductscience.org/library/genes/2261	Drugs and targets

1 to 10 of 71

See all 71 targets

Trials28

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04400474	Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study	Phase 2	93	2025-06-19	Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma	ATEZOLIZUMAB, CABOZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT04187404	A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma	Phase 1/2	70	2026-01-30	Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma	NIVOLUMAB, TIGOZERTINIB	Its record names the disease	ClinicalTrials.gov
NCT00566995	Phase II Study of Vandetanib in Individuals With Kidney Cancer	Phase 2	37	2015-03-11	Renal Cancer, Von Hippel Lindau	VANDETANIB	Its record names the disease	ClinicalTrials.gov
NCT00923481	A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	Phase 2	37	2012-08-29	Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell	FOSTAMATINIB DISODIUM	Its record names the disease	ClinicalTrials.gov
NCT02302833	Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery	Phase 2	21	2025-07-31	Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Regional Adrenal Gland Pheochromocytoma, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma	CABOZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT04711135	Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs	Phase 2	11	2024-11-27	Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma	LUTETIUM OXODOTREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT03165721	A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer	Phase 2	9	2021-05-10	Paraganglioma, Gastrointestinal Stromal Tumors, Carcinoma, Renal Cell, Renal Neoplasms, Pheochromocytoma	GUADECITABINE	Its record names the disease	ClinicalTrials.gov
NCT01340794	Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma	Phase 2	7	2016-07-21	Extra-Adrenal Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Paraganglioma, Recurrent Adrenal Gland Pheochromocytoma	PAZOPANIB HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT03008369	Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery	Phase 2	3	2021-05-14	Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma	LENVATINIB	Its record names the disease	ClinicalTrials.gov
NCT06683846	Ivonescimab in the Treatment of Multiple Advanced Tumors	Phase 2	400		Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma, Perivascular Epithelioid Cell Tumor, Malignant, Sarcoma, Urachal Cancer, Neuroendocrine Cancer, Basal Cell Carcinomas, Sarcomatoid Carcinoma, Penile Cancer, Adrenal Cortical Cancer, Germ Cell Cancer Metastatic, Non-Clear Cell Renal Cell Carcinoma, Prostate Cancers, Clear Cell Renal Cancer, Urothelial Carcinoma, Kidney Cancer, Rare Tumors	IVONESCIMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 28

See all 28 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
GEP-NET vs PPGL: Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera Administration	4 of 4	6 of 7	11	NCT04711135	Trial comparisons
Treatment: Pazopanib Without Run-in vs Treatment: Pazopanib With Run-in: serious adverse events	2 of 2	1 of 4	6	NCT01340794	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41124218	RESULT	1	PubMed
40198358	DERIVED	1	PubMed
38608693	DERIVED	1	PubMed
38402886	DERIVED	1	PubMed
36302175	DERIVED	1	PubMed
31322702	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008233

GET https://conductscience.org/api/diseases/v1/MONDO_0008233/drugs?page=2

API reference For AI assistants